Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172803 | 0.74 | PDE4B (0.52) | PDE4BPDE3AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2844148 | 0.71 | PDE4B (0.49) | PDE4BPDE3AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2962674 | 0.71 | PDE4B (0.61) | PDE4BPDE3APDE2A | |
| SCHEMBL2847047 | 0.68 | PDE4B (0.44) | PDE4BPDE3AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2962471 | 0.62 | PDE4B (0.70) | PDE4BPDE3A | |
| SCHEMBL4122533 | 0.61 | PDE4B (1.00) | PDE4BPDE3A | |
| SCHEMBL5405135 | 0.59 | PDE2A (0.45) | PDE2A | |
| SCHEMBL2255158 | 0.59 | NNMT (0.44) | PDE3APDE2A | |
| SCHEMBL21069019 | 0.58 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22357553 | 0.58 | JAK2 (0.36) | PDE4BPDE3ACCR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| EP-2168959-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE5A, PDE2A | PDE4B 8/4885PDE3A 1/4885PDE2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.